Advanced Melanoma Clinical Trials

105 clinical trials for Advanced Melanoma across international registries, including 24 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Clinical Study of T3011 in Subjects With Advanced Melanoma — RECRUITING · PHASE1
• Sitagliptin With Pembro in RCC and Melanoma — RECRUITING · PHASE1
• Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors — RECRUITING · PHASE1
• VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3] — RECRUITING · PHASE3
• High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial — RECRUITING · NA
• AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
• Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study — RECRUITING · PHASE4
• IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors — RECRUITING · PHASE1
• A Trial of LBL-024 Monotherapy, LBL-024 Combined With LBL-007 or Toripalimab in Patients With Advanced Melanoma — RECRUITING · PHASE1
• NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma — RECRUITING · PHASE1
• A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma — RECRUITING · PHASE2
• A Phase II Trial of LM103 in Advanced Melanoma — RECRUITING · PHASE2
• Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma. — RECRUITING · PHASE2
• Au-TMP and Radiotherapy for Advanced Melanoma With Anti-PD-1 Therapy — RECRUITING · PHASE1
• ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab — RECRUITING · PHASE4
• At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer — RECRUITING · PHASE2
• Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma — RECRUITING · PHASE2
• IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) — RECRUITING · PHASE3
• Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) — RECRUITING · PHASE3
• A Study of GC101 TIL in Advanced Melanoma (10hospital) — RECRUITING · PHASE1
• FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma — RECRUITING · PHASE1
• Naltrexone and Propranolol Combined With Immunotherapy — RECRUITING · PHASE1
• HS-IT101 Injection in the Treatment of Advanced Melanoma — RECRUITING · PHASE1
• Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo) — RECRUITING · PHASE2
• Study to compare the effect of ipilimumab retreatment with chemotherapy in advanced melanoma — COMPLETED · PHASE2
• A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Participants with Advanced Melanoma (TeLuRide-006) — TERMINATED · PHASE3
• Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery — ACTIVE_NOT_RECRUITING · PHASE2
• MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma. — NOT_YET_RECRUITING · PHASE2
• A Randomized, Controlled, Multicenter, Phase 3 Clinical Study Comparing Vusolimogene Oderparepvec in Combination with Nivolumab Versus Treatment of Physician’s Choice in Patients with Advanced Melanoma That Has Progressed on an Anti-PD-1 and an Anti-CTLA-4 Containing Treatment Regimen [IGNYTE-3] — TERMINATED · PHASE3
• Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial — ACTIVE_NOT_RECRUITING · PHASE2
• A Phase II, Open-Label, Multicenter, Non-Randomized Study Of The Efficacy And‬ Safety Of Enfortumab Vedotin In Combination With Pembrolizumab Previously Treated‬ Advanced Melanoma‬ — TERMINATED · PHASE2
• Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 — ACTIVE_NOT_RECRUITING · PHASE1
• The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors — SUSPENDED · PHASE1
• A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma — ACTIVE_NOT_RECRUITING · PHASE1
• CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma — TERMINATED · PHASE2
• A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC) — COMPLETED · PHASE1
• Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV — ACTIVE_NOT_RECRUITING · PHASE1
• Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma — ACTIVE_NOT_RECRUITING · PHASE2
• A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma — COMPLETED · PHASE1
• Efficacy of immunotherapy in melanoma patients with brain metastases treated with steroids. The MEMBRAINS trial — TERMINATED · PHASE2
• Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies — TERMINATED · PHASE1
• A Phase 1b, Randomized, Open-Label Trial to Evaluate Safety, Engraftment, and Initial Signs of Clinical Activity of MB097 in Combination with Pembrolizumab in Melanoma Patients with Primary Resistance to an Anti-PD-1-Containing Immunotherapy (MELODY-1) — TERMINATED · PHASE1
• Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma — COMPLETED
• ACT-TIL and ANV419 for Advanced Melanoma. — ACTIVE_NOT_RECRUITING · PHASE1
• Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma — COMPLETED · PHASE1
• Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study — COMPLETED
• A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma. — COMPLETED · PHASE2
• A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma — ACTIVE_NOT_RECRUITING · PHASE2
• An Expanded Access Program for VO (RP1) in Combination With Nivolumab in Patients With Advanced Melanoma — TERMINATED
• A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers — COMPLETED · PHASE1

Refine this search